ACAD - アカディア・ファ―マシュ―ティカルズ （ACADIA Pharmaceuticals Inc.） アカディア・ファ―マシュ―ティカルズACADのチャート
ACADの企業情報
| symbol | ACAD |
|---|---|
| 会社名 | Acadia Pharmaceuticals Inc （アカディア・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アカディア・ファーマシューティカルズ(ACADIA Pharmaceuticals Inc.)は神経と関連の中枢神経系疾患における満たされていない医療ニーズに応じた小分子薬事業を中心とするバイオ医薬品会社。同社は第III相開発段階におけるパーキンソン病精神病のためのファーストインクラスの治療薬である｢pimavanserin｣を含む４種類の製品候補を有する。同社は｢pimavanserin｣に対してグローバルな販売権を持つ。更に、同社はAllergan Inc.と連携して開発する慢性痛治療用の第II相試験にある薬品候補及び緑内障治療用の第I相試験にある薬品候補を有し、並びにMeiji Seika Kaisha Ltdと連携して開発する統合失調症治療用第I相開発段階における薬品候補も有する。同社の臨床段階における薬品候補は｢Pimavanserin｣、｢Alpha Adrenergic Agonists｣、｢Muscarinic Agonist｣と｢AM-831｣を含む。 アカディア・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。神経および関連中枢神経系疾患に対する治療薬に焦点を当て、主に、パ―キンソン病、精神分裂病、神経痛、アルツハイマ―病などの治療に関係する治療薬候補を開発する。本社は、カリフォルニア州サンディエゴ。 acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies |
| 本社所在地 | 3611 Valley Centre Drive Suite 300 San Diego CA 92130 USA |
| 代表者氏名 | Stephen R. Biggar スティーブン・R・ビガール |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 858-558-2871 |
| 設立年月日 | 34151 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2004年 |
| 従業員数 | 425人 |
| url | www.acadia-pharm.com |
| nasdaq_url | https://www.nasdaq.com/symbol/acad |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -251.19800 |
| 終値（lastsale） | 21.11 |
| 時価総額（marketcap） | 2638891922.53 |
| 時価総額 | 時価総額（百万ドル） 2645.142 |
| 売上高 | 売上高（百万ドル） 185.07100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2388.287 |
| 当期純利益 | 当期純利益（百万ドル） -182.79200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 ACADIA Pharmaceuticals Inc. revenues increased from $45.8M to $105.9M. Net loss decreased 24% to $117.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income net increase of 25% to $2.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.27 to -$0.94. |
ACADのテクニカル分析
ACADのニュース
Acadia Pharma Announces Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER Study Evaluating DAYBUE in Patients with Rett Syndrome 2023/06/08 15:17:02 Investing.com
https://www.investing.com/news/assorted/acadia-pharma-announces-nature-medicine-publishes-results-from-pivotal-phase-3-lavender-study-evaluating-daybue-in-patients-with-rett-syndrome-432SI-3101249
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER Study Evaluating DAYBUE (trofinetide) Efficacy and Safety in Patients with Rett Syndrome 2023/06/08 15:10:00 Wallstreet:Online
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nature Medicine published results from the pivotal Phase 3 LAVENDER trial, a 12-week randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of DAYBUE in patients with Rett syndrome five to 20 years of age. “The LAVENDER study was designed to measure the effect of DAYBUE treatment on the range of behavioral,
Raymond James Financial Services Advisors Inc. Acquires Position in ACADIA Pharmaceuticals Inc. 2023/06/08 12:20:53 Best Stocks
Raymond James Financial Services Advisors Inc. has recently announced its acquisition of a new position in ACADIA Pharmaceuticals Inc., according to their most recent filing with the Securities and Exchange Commission (SEC). This institutional investor obtained 14,670 shares of the biopharmaceutical company’s stock, which amounts to approximately $234,000 in value. ACADIA Pharmaceuticals, Inc is an […] The post Raymond James Financial Services Advisors Inc. Acquires Position in ACADIA Pharmaceuticals Inc. appeared first on Best Stocks .
3 Penny Stocks That Could Skyrocket in the Next 12 Months 2023/06/07 09:58:46 InvestorPlace
Penny stocks can be rewarding. Look at Acadia Pharmaceuticals (NASDAQ: ACAD ), for example. In 2012, it was working on a treatment for Parkinson’s Disease Psychosis and traded for less than $1. By 2015, it was up to $43 a share, a 4,200% return. Apple (NASDAQ: AAPL ), Ford Motor (NYSE: F ), Advanced Micro Devices (NASDAQ: AMD ) and even Novavax (NASDAQ: NVAX ) were all former penny stocks, too. In short, find the top penny stocks to buy, and you can make a fortune. Unfortunately, when it comes to top penny stocks to buy, there are also plenty of horrors. It’s why the U.S. SEC warns “Penny stocks may trade infrequently – which means that it may be difficult to sell penny stock shares once you have them. Because it may also be difficult to find quotations for penny stocks, they may be impossible to accurately price. Investors in penny stock[s] should be prepared for the possibility that they may lose their whole investment.” With that in mind, here are three top penny stocks to buy that could skyrocket in the next 12 months.
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference 2023/06/01 13:04:00 Wallstreet:Online
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7, 2023 at 10:00 a.m. Eastern Time in New York, NY. A live webcast of the presentation will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference 2023/06/01 13:04:00 Wallstreet:Online
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7, 2023 at 10:00 a.m. Eastern Time in New York, NY. A live webcast of the presentation will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately
ACADIA Pharmaceuticals''s Return On Capital Employed Insights 2023/05/23 14:47:05 Benzinga
ACADIA Pharmaceuticals (NASDAQ: ACAD ) brought in sales totaling $118.46 million during Q1 according to data provided by Benzinga Pro . However, earnings decreased 3.11%, resulting in a loss of $43.02 million. ACADIA Pharmaceuticals collected $136.49 million in revenue during Q4, but reported earnings showed a $41.73 million loss. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com
FY2023 EPS Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Decreased by HC Wainwright 2023/05/13 11:34:55 EIN News Pharmaceuticals
… . The consensus estimate for ACADIA Pharmaceuticals ’ current full-year earnings is … ’s stock. About ACADIA Pharmaceuticals (Get Rating) ACADIA Pharmaceuticals , Inc is a … analysts'' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat …
Research Analysts Offer Predictions for ACADIA Pharmaceuticals Inc.’s Q2 2023 Earnings (NASDAQ:ACAD) 2023/05/12 06:34:12 EIN News Pharmaceuticals
… . Institutional Trading of ACADIA Pharmaceuticals Institutional investors and hedge funds … and other institutional investors. ACADIA Pharmaceuticals Company Profile (Get Rating) … '' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat …
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2023 Earnings Call Transcript 2023/05/09 00:03:15 Seeking Alpha
ACADIA Pharmaceuticals Inc. (NASDAQ:NASDAQ:ACAD) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ETCompany ParticipantsMark Johnson - Vice President of Investor RelationsSteve Davis -…
The ACADIA Pharmaceuticals Inc. (ACAD) had a good session last reading, didn’t it? 2023/01/27 15:40:00 US Post News
As of Thursday, ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) stock closed at $18.66, down from $18.69 the previous day. While ACADIA Pharmaceuticals Inc. has underperformed by -0.16%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACAD fell by -16.88%, with highs and lows ranging from $28.06 to $12.24, […]
Acadia Pharmaceuticals: What''s Ahead In 2023 2023/01/16 19:04:11 Seeking Alpha
ACADIA Pharmaceuticals had one major disappointment in 2022 but has some potential new drug approvals on the horizon. Click here to read my analysis of ACAD.
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development 2023/01/09 14:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. Williamson will lead research and development at Acadia and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, Chief Executive Officer of Acadia. Dr. Williamson will succeed Dr. Srdjan Stankovic, whose planned retirement was announced last year. “We
Opening Bell Analysts Research Calls for Tuesday, January 3 2023/01/03 14:20:15 24/7 Wall street
This report was sent to Briefing.com subscribers earlier today. Research calls posted earlier this morning are available here. Upgrades: > ACADIA Pharmaceuticals (ACAD) upgraded to Buy from Neutral at Guggenheim; tgt $22 > Allegion (ALLE) upgraded to Buy from Hold at Vertical Research; tgt $128 > Becton Dickinson (BDX) upgraded to Buy from Neutral at […]
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics 2023/01/03 14:00:00 Wallstreet:Online
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’s disease psychosis (PDP) treated with NUPLAZID (pimavanserin) compared to other atypical antipsychotics over 12 months and across various subgroups. NUPLAZID is the only medication approved by the U.S.